X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALKEM LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALKEM LABORATORIES DISHMAN PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 25.1 - - View Chart
P/BV x 3.3 6.1 54.7% View Chart
Dividend Yield % 0.7 0.7 93.8%  

Financials

 DISHMAN PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
DISHMAN PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,589 23.6%   
Low Rs1291,232 10.5%   
Sales per share (Unadj.) Rs197.8417.5 47.4%  
Earnings per share (Unadj.) Rs21.256.3 37.7%  
Cash flow per share (Unadj.) Rs34.764.7 53.7%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.80.9 88.3%  
Book value per share (Unadj.) Rs179.9292.9 61.4%  
Shares outstanding (eoy) m80.69119.57 67.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.7%   
Avg P/E ratio x11.925.1 47.4%  
P/CF ratio (eoy) x7.221.8 33.2%  
Price / Book Value ratio x1.44.8 29.1%  
Dividend payout %9.422.6 41.8%   
Avg Mkt Cap Rs m20,306168,653 12.0%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3559,171 58.4%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96149,915 32.0%  
Other income Rs m2651,645 16.1%   
Total revenues Rs m16,22651,561 31.5%   
Gross profit Rs m4,1038,482 48.4%  
Depreciation Rs m1,0911,006 108.4%   
Interest Rs m944671 140.8%   
Profit before tax Rs m2,3348,451 27.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,606 38.8%   
Profit after tax Rs m1,7116,731 25.4%  
Gross profit margin %25.717.0 151.3%  
Effective tax rate %26.719.0 140.6%   
Net profit margin %10.713.5 79.5%  
BALANCE SHEET DATA
Current assets Rs m11,01827,062 40.7%   
Current liabilities Rs m9,51715,324 62.1%   
Net working cap to sales %9.423.5 40.0%  
Current ratio x1.21.8 65.6%  
Inventory Days Days11067 166.1%  
Debtors Days Days3541 84.4%  
Net fixed assets Rs m16,30412,610 129.3%   
Share capital Rs m161239 67.5%   
"Free" reserves Rs m12,90734,490 37.4%   
Net worth Rs m14,51635,027 41.4%   
Long term debt Rs m4,1891,212 345.8%   
Total assets Rs m29,80554,387 54.8%  
Interest coverage x3.513.6 25.5%   
Debt to equity ratio x0.30 834.4%  
Sales to assets ratio x0.50.9 58.3%   
Return on assets %8.913.6 65.5%  
Return on equity %11.819.2 61.3%  
Return on capital %17.524.9 70.5%  
Exports to sales %24.812.9 191.5%   
Imports to sales %3.73.1 121.1%   
Exports (fob) Rs m3,9566,461 61.2%   
Imports (cif) Rs m5961,540 38.7%   
Fx inflow Rs m4,9526,563 75.4%   
Fx outflow Rs m6973,012 23.1%   
Net fx Rs m4,2553,552 119.8%   
CASH FLOW
From Operations Rs m2,7867,259 38.4%  
From Investments Rs m-1,5291,864 -82.0%  
From Financial Activity Rs m-941-9,273 10.1%  
Net Cashflow Rs m316-150 -210.9%  

Share Holding

Indian Promoters % 61.4 66.9 91.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 33.1 11.2%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 0.0 -  
Shareholders   46,261 68,381 67.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - NOVARTIS COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS